Cart
sales@molnova.com
GS-9667
CAS No. 618380-90-8
GS-9667( —— )
Catalog No. M34268 CAS No. 618380-90-8
GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 172 | Get Quote |
|
| 5MG | 275 | Get Quote |
|
| 10MG | 376 | Get Quote |
|
| 25MG | 601 | Get Quote |
|
| 50MG | 821 | Get Quote |
|
| 100MG | 1107 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGS-9667
-
NoteResearch use only, not for human use.
-
Brief DescriptionGS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).
-
DescriptionGS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAdenosine Receptor
-
RecptorAdenosine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number618380-90-8
-
Formula Weight461.51
-
Molecular FormulaC21H24FN5O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO[C@H]1[C@H](N2C=3C(N=C2)=C(N[C@H]4[C@H](O)CCC4)N=CN3)O[C@H](CSC5=C(F)C=CC=C5)[C@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
ANR 94
ANR94 is a potent, selective antagonist of the adenosine A2A receptor (AA2AR), exhibiting a K_i value of 46 nM for the human AA2AR (hAA2AR).
-
Adenosine antagonist...
Adenosine antagonist-1 acts as an adenosine A3 receptor (AA3R) antagonist.
-
Ciforadenant
A potent, orally active, adenosine A2A receptor antagonist that is being investigated in solid tumors as a single agent and in combination with the anti-PD-L1 antibody atezolizumab.
